As oral selumetinib and other orally bioavailable MEK1/2 inhibitors with encouraging safety profiles are currently in clinical development for other indications [47,48], pilot trials in patients with EDMD and possibly other muscular dystrophies should be considered. The gene discussed is MAP2K1; the disease is muscular dystrophy.